膵臓fと呼ばれる外科的合併症を予防するための手術前のランレオチド対プラセボ
術後膵臓fの予防のためのランレオチドの無作為化第III相盲検試験
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Dana Sparks
- 電話番号:210-614-8808
- メール:dsparks@swog.org
研究連絡先のバックアップ
- 名前:Andrea Garcia
- 電話番号:210-614-8808
- メール:agarcia@swog.org
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 一時停止
- University of Alabama at Birmingham Cancer Center
-
Daphne、Alabama、アメリカ、36526
- 一時停止
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope、Alabama、アメリカ、36532
- 一時停止
- Thomas Hospital
-
Mobile、Alabama、アメリカ、36607
- 一時停止
- Mobile Infirmary Medical Center
-
Saraland、Alabama、アメリカ、36571
- 一時停止
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert、Arizona、アメリカ、85234
- 一時停止
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte、California、アメリカ、91010
- 一時停止
- City of Hope Comprehensive Cancer Center
-
La Jolla、California、アメリカ、92093
- 募集
- UC San Diego Moores Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:858-822-5354
- メール:cancercto@ucsd.edu
-
主任研究者:
- Andrew M. Lowy
-
Loma Linda、California、アメリカ、92357
- 一時停止
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles、California、アメリカ、90033
- 一時停止
- USC / Norris Comprehensive Cancer Center
-
San Diego、California、アメリカ、92103
- 一時停止
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark、Delaware、アメリカ、19718
- 一時停止
- Christiana Care Health System-Christiana Hospital
-
Newark、Delaware、アメリカ、19713
- 一時停止
- Helen F Graham Cancer Center
-
Newark、Delaware、アメリカ、19713
- 一時停止
- Medical Oncology Hematology Consultants PA
-
Wilmington、Delaware、アメリカ、19801
- 一時停止
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin、Florida、アメリカ、33570
- 一時停止
- Moffitt Cancer Center at SouthShore
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center - McKinley Campus
-
コンタクト:
- Site Public Contact
- 電話番号:800-679-0775
- メール:ClinicalTrials@moffitt.org
-
主任研究者:
- Andrew J. Sinnamon
-
Tampa、Florida、アメリカ、33607
- 一時停止
- Moffitt Cancer Center-International Plaza
-
Tampa、Florida、アメリカ、33612
- 一時停止
- Moffitt Cancer Center
-
Wesley Chapel、Florida、アメリカ、33544
- 一時停止
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- 一時停止
- Emory Saint Joseph's Hospital
-
Atlanta、Georgia、アメリカ、30308
- 一時停止
- Emory University Hospital Midtown
-
Atlanta、Georgia、アメリカ、30322
- 一時停止
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30303
- 一時停止
- Grady Health System
-
Johns Creek、Georgia、アメリカ、30097
- 一時停止
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Northwestern University
-
コンタクト:
- Site Public Contact
- 電話番号:312-695-1301
- メール:cancer@northwestern.edu
-
主任研究者:
- Akhil Chawla
-
Chicago、Illinois、アメリカ、60612
- 募集
- University of Illinois
-
主任研究者:
- Aslam Ejaz
-
コンタクト:
- Site Public Contact
- 電話番号:312-355-3046
-
Geneva、Illinois、アメリカ、60134
- 一時停止
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook、Illinois、アメリカ、60523
- 一時停止
- Northwestern Medicine Oak Brook
-
Orland Park、Illinois、アメリカ、60462
- 一時停止
- Northwestern Medicine Orland Park
-
Warrenville、Illinois、アメリカ、60555
- 一時停止
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 一時停止
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 募集
- University of Kentucky/Markey Cancer Center
-
主任研究者:
- Michael J. Cavnar
-
コンタクト:
- Site Public Contact
- 電話番号:859-257-3379
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- 一時停止
- University Medical Center New Orleans
-
-
Maryland
-
Elkton、Maryland、アメリカ、21921
- 一時停止
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- 一時停止
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、アメリカ、49017
- 一時停止
- Bronson Battle Creek
-
Grand Rapids、Michigan、アメリカ、49503
- 一時停止
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- 一時停止
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids、Michigan、アメリカ、49503
- 一時停止
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon、Michigan、アメリカ、49444
- 一時停止
- Trinity Health Muskegon Hospital
-
Niles、Michigan、アメリカ、49120
- 一時停止
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、アメリカ、49444
- 一時停止
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City、Michigan、アメリカ、49677
- 一時停止
- Corewell Health Reed City Hospital
-
Saint Joseph、Michigan、アメリカ、49085
- 一時停止
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、アメリカ、49085
- 一時停止
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming、Michigan、アメリカ、49519
- 一時停止
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin、Minnesota、アメリカ、56431
- 一時停止
- Riverwood Healthcare Center
-
Baxter、Minnesota、アメリカ、56425
- 一時停止
- Essentia Health - Baxter Clinic
-
Brainerd、Minnesota、アメリカ、56401
- 一時停止
- Essentia Health Saint Joseph's Medical Center
-
Crosslake、Minnesota、アメリカ、56442
- 一時停止
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River、Minnesota、アメリカ、56636
- 一時停止
- Essentia Health - Deer River Clinic
-
Detroit Lakes、Minnesota、アメリカ、56501
- 一時停止
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth、Minnesota、アメリカ、55805
- 一時停止
- Essentia Health Saint Mary's Medical Center
-
Duluth、Minnesota、アメリカ、55805
- 一時停止
- Miller-Dwan Hospital
-
Duluth、Minnesota、アメリカ、55805
- 一時停止
- Essentia Health Cancer Center
-
Ely、Minnesota、アメリカ、55731
- 一時停止
- Essentia Health - Ely Clinic
-
Fosston、Minnesota、アメリカ、56542
- 一時停止
- Essentia Health - Fosston
-
Hibbing、Minnesota、アメリカ、55746
- 一時停止
- Essentia Health Hibbing Clinic
-
International Falls、Minnesota、アメリカ、56649
- 一時停止
- Essentia Health - International Falls Clinic
-
Moose Lake、Minnesota、アメリカ、55767
- 一時停止
- Essentia Health - Moose Lake Clinic
-
Park Rapids、Minnesota、アメリカ、56470
- 一時停止
- Essentia Health - Park Rapids
-
Pequot Lakes、Minnesota、アメリカ、56472
- 一時停止
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River、Minnesota、アメリカ、56474
- 一時停止
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone、Minnesota、アメリカ、55072
- 一時停止
- Essentia Health Sandstone
-
Staples、Minnesota、アメリカ、56479
- 一時停止
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia、Minnesota、アメリカ、55792
- 一時停止
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington、Missouri、アメリカ、63640
- 募集
- Parkland Health Center - Farmington
-
主任研究者:
- Bryan A. Faller
-
コンタクト:
- Site Public Contact
- 電話番号:314-996-5569
-
Sainte Genevieve、Missouri、アメリカ、63670
- 募集
- Sainte Genevieve County Memorial Hospital
-
主任研究者:
- Bryan A. Faller
-
コンタクト:
- Site Public Contact
- 電話番号:314-996-5569
-
St Louis、Missouri、アメリカ、63131
- 募集
- Missouri Baptist Medical Center
-
主任研究者:
- Bryan A. Faller
-
コンタクト:
- Site Public Contact
- 電話番号:314-996-5569
-
Sullivan、Missouri、アメリカ、63080
- 募集
- Missouri Baptist Sullivan Hospital
-
主任研究者:
- Bryan A. Faller
-
コンタクト:
- Site Public Contact
- 電話番号:314-996-5569
-
Sunset Hills、Missouri、アメリカ、63127
- 募集
- BJC Outpatient Center at Sunset Hills
-
主任研究者:
- Bryan A. Faller
-
コンタクト:
- Site Public Contact
- 電話番号:314-996-5569
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- 一時停止
- University of Nebraska Medical Center
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- 一時停止
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston、New Jersey、アメリカ、07039
- 一時停止
- Saint Barnabas Medical Center
-
New Brunswick、New Jersey、アメリカ、08903
- 一時停止
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- 一時停止
- University of New Mexico Cancer Center
-
-
New York
-
Rochester、New York、アメリカ、14642
- 一時停止
- University of Rochester
-
Syracuse、New York、アメリカ、13210
- 一時停止
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- 一時停止
- Carolinas Medical Center/Levine Cancer Institute
-
Concord、North Carolina、アメリカ、28025
- 一時停止
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58103
- 一時停止
- Essentia Health Cancer Center-South University Clinic
-
Fargo、North Dakota、アメリカ、58122
- 一時停止
- Sanford Roger Maris Cancer Center
-
Fargo、North Dakota、アメリカ、58122
- 一時停止
- Sanford Broadway Medical Center
-
Jamestown、North Dakota、アメリカ、58401
- 一時停止
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- 一時停止
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus、Ohio、アメリカ、43210
- 一時停止
- Ohio State University Comprehensive Cancer Center
-
West Chester、Ohio、アメリカ、45069
- 一時停止
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18104
- 募集
- Saint Luke's Cancer Center - Allentown
-
コンタクト:
- Site Public Contact
- 電話番号:610-776-4714
-
主任研究者:
- Darius C. Desai
-
Bethlehem、Pennsylvania、アメリカ、18015
- 募集
- Saint Luke's University Hospital-Bethlehem Campus
-
コンタクト:
- Site Public Contact
- 電話番号:484-503-4151
-
主任研究者:
- Darius C. Desai
-
Chadds Ford、Pennsylvania、アメリカ、19317
- 一時停止
- Christiana Care Health System-Concord Health Center
-
Easton、Pennsylvania、アメリカ、18045
- 募集
- Saint Luke's Hospital-Anderson Campus
-
コンタクト:
- Site Public Contact
- 電話番号:888-823-5923
- メール:ctsucontact@westat.com
-
主任研究者:
- Darius C. Desai
-
Quakertown、Pennsylvania、アメリカ、18951
- 募集
- Saint Luke's Hospital - Upper Bucks Campus
-
コンタクト:
- Site Public Contact
- 電話番号:610-776-4714
-
主任研究者:
- Darius C. Desai
-
Stroudsburg、Pennsylvania、アメリカ、18360
- 募集
- Saint Luke's Hospital - Monroe Campus
-
コンタクト:
- Site Public Contact
- 電話番号:888-823-5923
- メール:ctsucontact@westat.com
-
主任研究者:
- Darius C. Desai
-
Wilkes-Barre、Pennsylvania、アメリカ、18711
- 一時停止
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57104
- 一時停止
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- 一時停止
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37920
- 一時停止
- University of Tennessee - Knoxville
-
Memphis、Tennessee、アメリカ、38120
- 一時停止
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington、Vermont、アメリカ、05405
- 一時停止
- University of Vermont and State Agricultural College
-
Burlington、Vermont、アメリカ、05401
- 一時停止
- University of Vermont Medical Center
-
-
Virginia
-
Richmond、Virginia、アメリカ、23235
- 募集
- VCU Massey Cancer Center at Stony Point
-
コンタクト:
- Site Public Contact
- メール:ctoclinops@vcu.edu
-
主任研究者:
- Leopoldo J. Fernandez
-
Richmond、Virginia、アメリカ、23298
- 募集
- VCU Massey Comprehensive Cancer Center
-
主任研究者:
- Leopoldo J. Fernandez
-
コンタクト:
- Site Public Contact
- 電話番号:804-628-6430
- メール:CTOclinops@vcu.edu
-
Roanoke、Virginia、アメリカ、24033
- 一時停止
- Carilion Roanoke Memorial Hospital
-
Winchester、Virginia、アメリカ、22601
- 一時停止
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- 一時停止
- University of Washington Medical Center - Montlake
-
Seattle、Washington、アメリカ、98109
- 一時停止
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland、Wisconsin、アメリカ、54806
- 一時停止
- Northwest Wisconsin Cancer Center
-
Ashland、Wisconsin、アメリカ、54806
- 一時停止
- Duluth Clinic Ashland
-
Hayward、Wisconsin、アメリカ、54843
- 一時停止
- Essentia Health-Hayward Clinic
-
Hayward、Wisconsin、アメリカ、54843
- 一時停止
- Tamarack Health Hayward Medical Center
-
Marshfield、Wisconsin、アメリカ、54449
- 募集
- Marshfield Medical Center-Marshfield
-
コンタクト:
- Site Public Contact
- 電話番号:800-782-8581
- メール:oncology.clinical.trials@marshfieldresearch.org
-
主任研究者:
- Jessica A. Wernberg
-
Mukwonago、Wisconsin、アメリカ、53149
- 一時停止
- ProHealth D N Greenwald Center
-
Oconomowoc、Wisconsin、アメリカ、53066
- 一時停止
- ProHealth Oconomowoc Memorial Hospital
-
Spooner、Wisconsin、アメリカ、54801
- 一時停止
- Essentia Health-Spooner Clinic
-
Superior、Wisconsin、アメリカ、54880
- 一時停止
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha、Wisconsin、アメリカ、53188
- 一時停止
- ProHealth Waukesha Memorial Hospital
-
Waukesha、Wisconsin、アメリカ、53188
- 一時停止
- UW Cancer Center at ProHealth Care
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
他の名前:
Undergo distal pancreatectomy Given SC
他の名前:
|
|
プラセボコンパレーター:Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
他の名前:
Undergo distal pancreatectomy Given SC
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
時間枠:Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of biochemical leak (BL)
時間枠:Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
時間枠:From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
時間枠:At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in pancreatic specific QOL
時間枠:At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
時間枠:At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
時間枠:Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
時間枠:Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
時間枠:From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
時間枠:Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Jonathan G Sham、SWOG Cancer Research Network
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- S2408
- UG1CA189974 (米国 NIH グラント/契約)
- NCI-2024-08361 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (その他の識別子:DCP)
- S2408 (その他の識別子:SWOG)
- S2408 (その他の識別子:CTEP)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。